anti-LILRB2-antibody(OncoResponse)

N/A

Report date: 2022/07/01 15:29:28

Base Information

Drug Nameanti-LILRB2-antibody(OncoResponse)
Drug Alias Nameanti-LILRB2-antibody(OncoResponse)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionLeukocyte immunoglobulin-like receptor subfamily B member 2 inhibitors
TargetsLeukocyte immunoglobulin-like receptor subfamily B member 2
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesOncResponse Inc
China Registration ClassN/A

Develop Information

Active CompaniesOncResponse Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A